Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Catvan Le

Interventional Pain Medicine Somerset, NJ Medical Doctor

NPI 1457593477 CMS profile 65764

33 Clyde Rd, Suites 105-106, Somerset, NJ 08873

Open in the dashboard

General payments

$3,347

196 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Catvan Le of Somerset, NJ is reported in the CMS Open Payments database as having received $3,347 across 196 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 45th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $111 4
2021 General $1,108 26
2020 General $1,109 93
2019 General $1,020 73

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Catvan Le
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Catvan Le were reported at $0. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Catvan Le Interventional Pain Medicine median Middle half National median
2019 $1,020 $684 $216–$2,079 $163
2020 $1,109 $382 $122–$1,109 $114
2021 $1,108 $552 $167–$1,554 $132
2022 $111 $605 $187–$1,924 $149
2023 $0 $671 $195–$1,915 $160
2024 $0 $684 $206–$1,837 $164
2025 $0 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Boston Scientific Corporation $440 9 payments
  2. Teva Pharmaceuticals USA, Inc. $312 55 payments
  3. Allergan Inc. $289 23 payments
  4. NuVasive, Inc. $256 2 payments
  5. Nevro Corp. $216 10 payments
  6. Medtronic, Inc. $201 2 payments
  7. Scilex Pharmaceuticals Inc. $187 14 payments
  8. TerSera Therapeutics LLC $176 13 payments
  9. SI-BONE, Inc. $149 4 payments
  10. Abbott Laboratories $144 3 payments
  11. Other $979 61 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $3,347 196 payments
Products named General payments · program years 2019–2022
  1. AJOVY $200 33 payments
  2. BOTOX $177 14 payments
  3. PRIALT $176 13 payments
  4. COHERE $154 1 payment
  5. SPECTRA WAVEWRITER $150 4 payments
  6. IFUSE IMPLANT $149 4 payments
  7. GENERAL PAIN MANAGEMENT $135 2 payments
  8. WAVEWRITER ALPHA $124 1 payment
  9. MYSTIM $123 2 payments
  10. AIMOVIG $123 8 payments
  11. Other $1,920 120 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$22,894

Medicare's payments for the services billed

Medicare patients

148

Average age 77

Services billed

173

78 women, 70 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 64%
Chronic kidney disease 43%
Ischemic heart disease 41%
Depression 40%
Diabetes 39%
Atrial fibrillation 39%
Heart failure 37%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

196 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record